Our results are consistent with this, Dec and Aza enhanced the cytotoxicity of CD44v6 CAR-T against AML cells in vitro and in vivo, by promoting CD44v6 expression in AML cells regardless of FLT3 or DNMT3A mutations. This evidence concerns the gene DNMT3A and acute myeloid leukemia.